Shares of Teladoc Health Inc (NYSE:TDOC) traded down 10.4% on Monday following insider selling activity. The stock traded as low as $52.86 and last traded at $52.94. 2,813,223 shares changed hands during mid-day trading, an increase of 111% from the average session volume of 1,335,448 shares. The stock had previously closed at $59.08.

Specifically, SVP Andrew Turitz sold 8,202 shares of the company’s stock in a transaction dated Tuesday, September 4th. The shares were sold at an average price of $77.42, for a total value of $634,998.84. Following the completion of the sale, the senior vice president now owns 9,378 shares of the company’s stock, valued at $726,044.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Adam C. Vandervoort sold 5,550 shares of the company’s stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $77.67, for a total transaction of $431,068.50. Following the completion of the sale, the insider now directly owns 2,934 shares of the company’s stock, valued at approximately $227,883.78. The disclosure for this sale can be found here. In the last three months, insiders have sold 210,929 shares of company stock valued at $15,224,945. Corporate insiders own 3.95% of the company’s stock.

TDOC has been the subject of several research analyst reports. SunTrust Banks upped their price objective on shares of Teladoc Health to $77.00 and gave the stock a “buy” rating in a report on Thursday, August 9th. Chardan Capital upped their price objective on shares of Teladoc Health from $73.00 to $86.00 and gave the stock a “buy” rating in a report on Friday, August 3rd. Canaccord Genuity reaffirmed a “buy” rating and issued a $70.00 price objective on shares of Teladoc Health in a report on Thursday, August 2nd. Wells Fargo & Co reaffirmed a “buy” rating and issued a $70.00 price objective on shares of Teladoc Health in a report on Thursday, August 2nd. Finally, Citigroup upped their price objective on shares of Teladoc Health from $80.00 to $88.00 and gave the stock a “buy” rating in a report on Friday, September 21st. Four analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. Teladoc Health currently has a consensus rating of “Buy” and an average price target of $82.95.

The company has a current ratio of 8.99, a quick ratio of 8.99 and a debt-to-equity ratio of 0.40. The stock has a market capitalization of $4.14 billion, a P/E ratio of -32.08 and a beta of 0.96.

Teladoc Health (NYSE:TDOC) last issued its quarterly earnings results on Thursday, November 1st. The health services provider reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.02. Teladoc Health had a negative net margin of 31.32% and a negative return on equity of 14.05%. The firm had revenue of $111.00 million for the quarter, compared to analysts’ expectations of $109.94 million. During the same period in the previous year, the business earned ($0.55) earnings per share. Teladoc Health’s revenue for the quarter was up 61.6% compared to the same quarter last year. As a group, sell-side analysts expect that Teladoc Health Inc will post -1.47 EPS for the current fiscal year.

A number of institutional investors have recently modified their holdings of the business. Riverhead Capital Management LLC raised its position in Teladoc Health by 2.0% in the third quarter. Riverhead Capital Management LLC now owns 44,243 shares of the health services provider’s stock worth $3,821,000 after acquiring an additional 857 shares in the last quarter. Oppenheimer Asset Management Inc. raised its position in Teladoc Health by 9.7% in the third quarter. Oppenheimer Asset Management Inc. now owns 9,789 shares of the health services provider’s stock worth $845,000 after acquiring an additional 862 shares in the last quarter. CWM LLC raised its position in Teladoc Health by 2.1% in the second quarter. CWM LLC now owns 53,632 shares of the health services provider’s stock worth $3,113,000 after acquiring an additional 1,078 shares in the last quarter. Swiss National Bank raised its position in Teladoc Health by 1.2% in the third quarter. Swiss National Bank now owns 97,900 shares of the health services provider’s stock worth $8,454,000 after acquiring an additional 1,200 shares in the last quarter. Finally, HAP Trading LLC raised its position in Teladoc Health by 6.8% in the third quarter. HAP Trading LLC now owns 19,650 shares of the health services provider’s stock worth $1,697,000 after acquiring an additional 1,250 shares in the last quarter.

TRADEMARK VIOLATION NOTICE: “Teladoc Health (TDOC) Stock Price Down 10.4% After Insider Selling” was reported by Daily Political and is the property of of Daily Political. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://www.dailypolitical.com/2018/11/19/teladoc-health-tdoc-stock-price-down-10-4-after-insider-selling.html.

About Teladoc Health (NYSE:TDOC)

Teladoc Health, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

See Also: What is a stock split?

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.